Biotek-snakken — December 2024
-
Biotekfirma gør klar til børsentré med nye profiler i bestyrelsen https://borsen.dk/nyheder/virksomheder/biotekfirma-gor-klar-til-borsentre-med-nye-profiler-i-bestyrelsen?b_source=borsen&b_medium=row_0&b_campaign=list_1
-
Why NovoCure Stock Was Winning Big This Week https://proinvestor.com/investornyt/1251361/why-novocure-stock-was-winning-big-this-week
-
Infant Bacterial Therapeutics data fra undersøgelsen vil blive præsenteret på Hot Topics in Neonatology, i dag den 9. december af professor Josef Neu. https://hottopicsinneonatology.nemours.org/
-
Bud på: Abliva - oppe med +200% i dag ...
Statement by the Board of Directors of Abliva regarding the public cash offer from Pharming
Abliva – Delivering mitochondrial health
Abliva develops medicines for the treatment of primary mitochondrial diseases.
(abliva.com)
Research & Development
Research & Development – Abliva
Abliva’s in-house R&D capabilities have been instrumental in creating and delivering a portfolio that includes several projects with mechani ...
(abliva.com)
-
Medivir obtains IND approval for fostrox - the first oral, liver-targeted treatment for advanced liver cancer
Jeg har taget en pæn position i svenske Medivir i dag med baggrund i deres pressemeddelelse. Skrevet efter luk ...
-
Medivirs vd: “IND-godkännandet är en mycket viktig milstolpe”
Medivir: IND Approval for Phase IIb
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind